Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | CALML3 | P27482 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | SDHA | P31040 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393031 | 1.00 | MAOA (0.55) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL14026522 | 1.00 | MAOA (0.55) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL5172507 | 0.91 | MAOA (0.50) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL15507021 | 0.91 | MAOA (0.50) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL10197354 | 0.91 | CALML3 (0.51) | MAOACALML3MAOBF10CYP3A4 | |
| SCHEMBL5742734 | 0.88 | MAOA (0.55) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL14432711 | 0.86 | MAOA (0.51) | MAOACALML3MAOBPTGS1SDHA | |
| SCHEMBL14769803 | 0.86 | CALML3 (0.51) | MAOACALML3MAOBF10CYP3A4 | |
| SCHEMBL10197356 | 0.86 | CALML3 (0.51) | MAOACALML3MAOBF10CYP3A4 | |
| SCHEMBL5742729 | 0.85 | CALML3 (0.43) | MAOACALML3MAOBF10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | MAOA 824/4885CALML3 4706/4885MAOB 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.